Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 10/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8835042 | 0.94 | KCNJ1 (0.47) | KCNJ1KCNH2HRH3MAPTKMT2A | |
| SCHEMBL6071728 | 0.74 | CYP19A1 (0.48) | KMT2ASIGMAR1 | |
| SCHEMBL5795346 | 0.72 | KDM1A (0.48) | MAPTKMT2AALDH1A1POLB | |
| SCHEMBL5795242 | 0.72 | KCNJ1 (0.46) | KCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL6072350 | 0.71 | ALDH1A1 (0.39) | HRH3KMT2ASIGMAR1KDM4EALDH1A1 | |
| SCHEMBL2723268 | 0.71 | KCNJ1 (1.00) | KCNJ1KCNH2HRH3MAPTSIGMAR1 | |
| SCHEMBL6071882 | 0.70 | CYP19A1 (0.45) | KMT2ASIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL286767 | 0.70 | KCNJ1 (0.97) | KCNJ1KCNH2HRH3MAPTSIGMAR1 | |
| SCHEMBL9015442 | 0.70 | KCNJ1 (0.97) | KCNJ1KCNH2HRH3MAPTSIGMAR1 | |
| SCHEMBL8554661 | 0.70 | KCNJ1 (0.97) | KCNJ1KCNH2HRH3MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | claimed |
| WO-1997040025-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED 1,2,3-TRIAZOLES AND OF ARRAYS OF SUBSTITUTED 1,2,3-TRIAZOLES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | KCNJ1 72/4885KCNH2 66/4885HRH3 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.